Opinion PaperTDM Is Alive and Kicking!Lemaitre, Florian PharmD, PhD*,†; Hesselink, Dennis A. MD, PhD‡ Author Information *Univ Rennes, CHU Rennes, Inserm, EHESP; †INSERM, Centre d'Investigation Clinique 1414, Rennes, France; and ‡Erasmus MC Transplant Institute, Rotterdam, the Netherlands. Correspondence: Florian Lemaitre, Department of Pharmacology, Rennes University Hospital, Hôpital Pontchaillou, 2, rue Henri Le Guilloux, 35033 Rennes, Cedex (e-mail: [email protected]). F. Lemaitre has received research grants (paid to the institution) from Astellas Pharma, Chiesi Pharma, and Sandoz and has received fees to attend meetings from Pfizer and Chiesi Pharma. During the last three years, D.A. Hesselink has received lecture and consulting fees from Astellas Pharma, Chiesi Pharma, Medincell, Novartis Pharma, and Sangamo Therapeutics. He received grant support from Astellas Pharma and Chiesi Pharma (paid to his institution). D.A. Hesselink does not have employment or stock ownership at any of these companies, nor does he have patents or patent applications. Therapeutic Drug Monitoring 45(1):p 3-5, February 2023. | DOI: 10.1097/FTD.0000000000001034 Buy Metrics Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.